| Name | Title | Contact Details |
|---|
Lowe Healthcare Worldwide is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Collective Medical empowers care teams to improve patient outcomes by closing the communication gaps that undermine patient care through seamless collaboration. With a nationwide network engaged with every national health plan in the country, hundreds of hospitals and health systems and tens of thousands of providers—including hospitals, emergency departments, skilled nursing facilities, primary care providers, mental and behavioral health clinics, and others—Collective Medical`s system-agnostic platform is trusted by healthcare organizations and payers to identify at-risk and complex patients and facilitate actionable collaboration to make better care decisions and improve outcomes. Based in Salt Lake City, Collective Medical is proven to streamline transitions of care, improve coordination across diverse care teams, and reduce unnecessary hospital admissions.
Small Bone Innovations, LLC (Main) Corp HQ is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Small Bone Innovations, LLC (Main) Corp HQ is based in New York, NY. You can find more information on Small Bone Innovations, LLC (Main) Corp HQ at www.totalsmallbone.com
House Research Insitute is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III